Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of “Buy” by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $54.20.

TARS has been the topic of several recent research reports. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th.

Institutional Trading of Tarsus Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Cowen AND Company LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 3.5% during the second quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after purchasing an additional 74,855 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 14.5% during the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock valued at $66,398,000 after purchasing an additional 231,131 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Tarsus Pharmaceuticals by 7.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after purchasing an additional 77,825 shares during the last quarter. Finally, Ikarian Capital LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 28.7% during the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after purchasing an additional 230,000 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ TARS opened at $50.32 on Friday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -13.21 and a beta of 1.04. Tarsus Pharmaceuticals has a 12-month low of $15.89 and a 12-month high of $52.99. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock’s 50 day simple moving average is $42.13 and its 200 day simple moving average is $33.63.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.